

Sitanshu S Singh

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8684683/sitanshu-s-singh-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

197
citations

9
h-index

13
g-index

24
ext. papers

306
ext. citations

4.8
avg, IF

3.58
L-index

#	Paper	IF	Citations
22	GHRH antagonists support lung endothelial barrier function. <i>Tissue Barriers</i> , 2019 , 7, 1669989	4.3	32
21	Fisetin, a 3,7,3',4'-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models. <i>Cells</i> , 2019 , 8,	7.9	23
20	Synthesis, Characterization, and Evaluation of Near-IR Boron Dipyrromethene Bioconjugates for Labeling of Adenocarcinomas by Selectively Targeting the Epidermal Growth Factor Receptor. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 3323-3335	8.3	19
19	Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor. <i>Pharmacological Research</i> , 2020 , 158, 104847	10.2	16
18	Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment. <i>Journal of Controlled Release</i> , 2021 , 329, 624-644	11.7	15
17	Proximity ligation assay to study protein-protein interactions of proteins on two different cells. <i>BioTechniques</i> , 2018 , 65, 149-157	2.5	13
16	A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization. <i>Oncotarget</i> , 2017 , 8, 74244-74262	3.3	11
15	Peptide ligands for targeting the extracellular domain of EGFR: Comparison between linear and cyclic peptides. <i>Chemical Biology and Drug Design</i> , 2018 , 91, 605-619	2.9	10
14	(-)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer. <i>Nutrients</i> , 2020 , 12,	6.7	9
13	Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. <i>Current Medicinal Chemistry</i> , 2020 , 27, 5274-5316	4.3	9
12	Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3. <i>Journal of Peptide Science</i> , 2018 , 24, e3066	2.1	7
11	A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models. <i>European Journal of Medicinal Chemistry</i> , 2021 , 216, 113312	6.8	7
10	Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design. <i>Advances in Protein Chemistry and Structural Biology</i> , 2018 , 111, 1-59	5.3	4
9	Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	4
8	Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2 + cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018 , 28, 3506-3513	2.9	4
7	Targeting EGFR Overexpression at the Surface of Colorectal Cancer Cells by Exploiting Amidated BODIPY-Peptide Conjugates. <i>Photochemistry and Photobiology</i> , 2020 , 96, 581-595	3.6	3
6	studies of a peptidomimetic that targets EGFR dimerization in NSCLC. <i>Journal of Cancer</i> , 2020 , 11, 5982-5999	4.9	3

5	A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2 ⁺ Cancer.. <i>International Journal of Pharmaceutics</i> , 2021 , 612, 121364	6.5	2
4	Click Conjugation of Boron Dipyrromethene (BODIPY) Fluorophores to EGFR-Targeting Linear and Cyclic Peptides. <i>Molecules</i> , 2021 , 26,	4.8	2
3	Mini-Review: PDPK1 (3-phosphoinositide dependent protein kinase-1), An Emerging Cancer Stem Cell Target. <i>Journal of Cancer Treatment & Diagnosis</i> , 2021 , 5, 30-35	2.1	1
2	Quinazoline-tethered hydrazone: A versatile scaffold toward dual anti-TB and EGFR inhibition activities in NSCLC. <i>Archiv Der Pharmazie</i> , 2021 , 354, e2100281	4.3	1
1	Targeting protein-protein interaction for immunomodulation: A sunflower trypsin inhibitor analog peptidomimetic suppresses RA progression in CIA model. <i>Journal of Pharmacological Sciences</i> , 2022 , 149, 124-138	3.7	